Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients

Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients

Show other versions (1)

Patients with inactive or occult hepatitis B virus infection and onco-hematological malignancies are at risk for hepatitis flare, hepatic failure and death due to chemotherapy-mediated reactivation. Nucleot(s)ide analogues can reduce reactivation risks and/or hepatitis. However, immuno-mediated phen...

Full description

Bibliographic Details
Main Authors:	Alfredo Marzano, Andrea Marengo, Michela di Fonzo, Antonella Ferrari, Bruno Monarca, Gianfranco delle Fave, Massimo Marignani
Format:	Article
Language:	English
Published:	PAGEPress Publications 2010-12-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	HBV hematology hepatitis flare chemotherapy
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/167

Similar Items

Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients
by: Michela di Fonzo, et al.
Published: (2010-02-01)

HBV genotypes and antiviral therapy of hepatitis B
by: I.A. Zaitsev, et al.
Published: (2019-09-01)

Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection
by: Cao, Z., et al.
Published: (2022)

Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management
by: Alessandra Zannella, et al.
Published: (2019-09-01)

Two cases of paralitic ileus in onco-hematologic patients
by: Francesca Carraro, et al.
Published: (2012-01-01)

Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia
by: A.F. Tiburcio Ribeiro, et al.
Published: (2013-02-01)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
by: Romina Salpini, et al.
Published: (2020-02-01)

Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure
by: Joseph Yoo, et al.
Published: (2018-04-01)

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
by: Ping Li, et al.
Published: (2021-07-01)

Fungal and viral oral infections in individuals with onco-hematologic neoplasms in a University Hospital
by: Thaiane Dantas Dias dos Santos, et al.
Published: (2017-09-01)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
by: Erik De Clercq, et al.
Published: (2010-05-01)

The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model
by: Lei Li, et al.
Published: (2017-10-01)

No evidence for occult HBV infection in hepatitis B vaccine non-responders
by: Mohammad Reza Aghasadeghi, et al.
Published: (2014-10-01)

A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals
by: Laura Ambra Nicolini, et al.
Published: (2019-09-01)

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report
by: Jürgen Kurt Rockstroh, et al.
Published: (2010-07-01)

Real-time PCR per HBV DNA: valutazione del nuovo sistema automatizzato COBAS AMPLIPREP™/COBAS TAQMAN™ HBV
by: Tiziano Allice, et al.
Published: (2007-12-01)

Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
by: Kai-Xuan Liu, et al.
Published: (2021-02-01)

Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review
by: Stéphanie Leroux, et al.
Published: (2021-04-01)

HBV mutations in EnhII/BCP/PC region contribute to the prognosis of hepatocellular carcinoma
by: Zijun Ge, et al.
Published: (2019-06-01)

Using the Quantitative Determination of HbsAg to Monitor Antiviral Therapy of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-04-01)

T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model
by: Xiuxiu Sang, et al.
Published: (2017-05-01)

Viral Factors Associated with Occult HBV in HIV-positive South Africans
by: Powell, Eleanor A.
Published: (2015)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
by: Emilia Hadziyannis, et al.
Published: (2018-09-01)

HBV-Infection and Pregnancy
by: H. Matejko, et al.
Published: (2017-10-01)

Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01)

Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes
by: Francisco Campello do Amaral Mello, et al.
Published: (2012-05-01)

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)
by: Mariantonietta Pisaturo, et al.
Published: (2019-09-01)

The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry
by: Yeping Sun, et al.
Published: (2018-09-01)

HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review
by: Giuseppe Gentile, et al.
Published: (2019-11-01)

HBV-Specific Adaptive Immunity
by: Adam J. Gehring, et al.
Published: (2009-07-01)

Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand
by: Avihingsanon Anchalee, et al.
Published: (2012-03-01)

Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment
by: Shingo Nakamoto, et al.
Published: (2014-11-01)

Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment
by: Zhang Dake, et al.
Published: (2012-12-01)

Prevalence of Occult and Mutant HBV Infection in Hospitalized Haematological Patients
by: Semenenko T.A., et al.
Published: (2016-02-01)

Evans Blue Inhibits HBV Replication Through a Dual Antiviral Mechanism by Targeting Virus Binding and Capsid Assembly
by: Yu Xiao, et al.
Published: (2019-11-01)

Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers
by: Romina Salpini, et al.
Published: (2020-11-01)

Advances in immunomodulating therapy of HBV infection
Published: (2005-01-01)

The function of HBx in HBV-induced hepatocellular carcinoma
by: Lu Zhaoliang
Published: (2018-04-01)

Risk of occupational exposure to the HBV infection in non-clinical healthcare personnel
by: Weronika Rymer, et al.
Published: (2016-06-01)

Glucocorticoid Withdrawal in Lupus Nephritis: A Study Protocol and Literature Review
by: Natalia Chu Oi Ciang, et al.
Published: (2020-12-01)

Cannot write session to /tmp/vufind_sessions/sess_6okth5avb0uvl7io85urub575c